Evidence map›Paper›PMID 28082342›Full record

Trial reportHaematologica2017

Second-line rituximab, lenalidomide, and bendamustine in mantle cell lymphoma: a phase II clinical trial of the Fondazione Italiana Linfomi.

Francesco Zaja, Simone Ferrero, Caterina Stelitano, Angela Ferrari, Flavia Salvi, Annalisa Arcari, Gerardo Musuraca, Barbara Botto, Michele Spina, Claudia Cellini and 12 more

Open access · goldAbstract readClinical Trial, Phase IILetter
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Haematologica, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
  6. IMiDs New and Old.Current hematologic malignancy reports · 2019
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 14 institutions in 1 country.

Francesco ZajaClinica Ematologica Centro Trapianti e Terapie Cellulari, DAME, DAME, Azienda Sanitaria-Universitaria Integrata, Udine, Italy francesco.zaja@asuiud.sanita.fvg.it.
Simone FerreroDivisione di Ematologia, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Università di Torino, Italy.
Caterina StelitanoDivisione di Ematologia, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Angela FerrariSC Ematologia Azienda Ospedaliera Santa Maria Nuova, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Reggio Emilia, Italy.
Flavia SalviSC Ematologia Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
Annalisa ArcariUnità di Ematologia Ospedale Civile G. Da Saliceto, Piacenza, Italy.
Gerardo MusuracaIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy.
Barbara BottoSC Ematologia Azienda Ospedaliera Città della Salute e della Scienza, Torino, Italy.
Michele SpinaCentro di Riferimento Oncologico (CRO), Aviano, Italy.
Claudia CelliniEmatologia Ospedale Santa Maria delle Croci, Ravenna, Italy.
Caterina PattiDivisione di Ematologia, Azienda Ospedali Riuniti Villa Sofia Cervello, Palermo, Italy.
Anna M LiberatiSC Oncoematologia Azienda Ospedaliera Santa Maria, Terni, Italy.
Claudia MinottoDipartimento di Scienze Mediche, UOC di Oncologia ed Ematologia Oncologica, Mirano, Italy.
Stefano A PileriDipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università degli Studi, Bologna, Italy.
Manuela CeccarelliSCDU Epidemiologia dei Tumori, Università degli Studi, Torino, Italy.
Stefano VolpettiClinica Ematologica Centro Trapianti e Terapie Cellulari, DAME, DAME, Azienda Sanitaria-Universitaria Integrata, Udine, Italy.
Antonella FerrantiSegreteria Fondazione Italiana Linfomi Onlus, Alessandria, Italy.
Daniela DrandiDivisione di Ematologia, Dipartimento di Biotecnologie Molecolari e Scienze della Salute, Università di Torino, Italy.
Elisa MontechiarelloDivisione di Ematologia, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Marco LadettoSC Ematologia, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.
James CarmichaelJames Carmichael, Celgene Institute for Translational Research Europe, Seville, Spain.
Renato FaninClinica Ematologica Centro Trapianti e Terapie Cellulari, DAME, DAME, Azienda Sanitaria-Universitaria Integrata, Udine, Italy.
Azienda Sanitaria Universitaria Integrata di Trieste · ITUniversity of Turin · ITAzienda ospedaliera "Bianchi-Melacrino-Morelli" · ITAzienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo · ITAzienda Ospedaliera Citta' della Salute e della Scienza di Torino · ITAzienda Ospedaliera S.Maria · ITCentro di Riferimento Oncologico · ITFondazione Intergruppo Italiano Linfomi Onlus · ITGuglielmo da Saliceto Hospital · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITIstituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori · ITOspedale Santa Maria · ITOspedale Vincenzo Cervello · ITUniversity of Bologna · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBendamustine HydrochlorideFemaleHumansKaplan-Meier EstimateLenalidomideLymphoma, Mantle-CellMaleMiddle AgedNeoplasm StagingRetreatmentRituximabThalidomideTreatment OutcomeBendamustine HydrochlorideLenalidomideRituximabThalidomide

Identifiers

PMID28082342
PMCPMC5477625
OpenAlexW2579576522

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.